Examples of using Myelosuppression in English and their translations into Polish
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Neurobehavioural development and reproductive capacity were unaffected when neonatal/juvenile rats were treated at dose levels inducing myelosuppression.
Infections and malignancies causing myelosuppression Neutropenia may be due to bone marrow infiltrating opportunistic infections such as Mycobacterium avium complex
Patients treated with TMZ may experience myelosuppression, including prolonged pancytopenia,
When given as a longer infusion, increased myelosuppression may be seen in patients with moderate to severe hepatic impairment.
Myelosuppression leading to sepsis and fatalities due to sepsis have been
Myelosuppression should/can be managed by withholding bosutinib temporarily,
Myelosuppression Treatment with Tasigna is associated with(National Cancer Institute Common Toxicity Criteria grade 3-4)
You must not use LITAK with other medicines that affect the production of blood cells in the bone marrow myelosuppression.
Discontinuation due to myelosuppression was infrequent thrombocytopenia 4.5%,
Temodal must not be used in patients with severe myelosuppression a condition in which the bone marrow cannot make enough blood cells.
other antimetabolites has been shown to potentiate myelosuppression.
Myelosuppression was generally reversible
Myelosuppression events, peripheral neuropathy events,
Patients may continue therapy during periods of reversible chemotherapy-induced myelosuppression but they should be monitored carefully for complications of neutropenia during this time.
Higher than recommended repeat doses are associated with increased myelosuppression including leukopenia, anaemia and thrombocytopenia.
Myelosuppression and adverse events related to myelosuppression(thrombocytopaenia,
during periods of reversible, chemotherapy-induced myelosuppression but they should be monitored carefully for complications of neutropenia during this time.
Toxic ranges of myelosuppression as described in section 4.2. Breast-feeding see section 4.6.
The safety and efficacy of Lonquex have not been evaluated in patients receiving chemotherapy associated with delayed myelosuppression, e.g. nitrosoureas.
Patients may continue therapy during periods of reversible, chemotherapy-induced myelosuppression butthey should be monitored carefully for complications of neutropenia during this time.